Free Trial

Century Therapeutics (IPSC) Competitors

Century Therapeutics logo
$0.63 -0.03 (-5.17%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$0.62 -0.01 (-0.90%)
As of 07/25/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IPSC vs. FDMT, YMAB, OGI, ENGN, RAPT, CTMX, CYBN, SXTC, CRBU, and EPRX

Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), Organigram Global (OGI), enGene (ENGN), Rapt Therapeutics (RAPT), CytomX Therapeutics (CTMX), Cybin (CYBN), China SXT Pharmaceuticals (SXTC), Caribou Biosciences (CRBU), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry.

Century Therapeutics vs. Its Competitors

Century Therapeutics (NASDAQ:IPSC) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Century Therapeutics has a net margin of -19.10% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. Century Therapeutics' return on equity of -10.71% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Century Therapeutics-19.10% -10.71% -5.96%
4D Molecular Therapeutics -767,126.06%-33.26%-30.68%

Century Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.81, indicating that its share price is 181% more volatile than the S&P 500.

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 5.0% of Century Therapeutics shares are owned by insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Century Therapeutics. MarketBeat recorded 5 mentions for 4D Molecular Therapeutics and 1 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.43 beat 4D Molecular Therapeutics' score of 0.65 indicating that Century Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Century Therapeutics Positive
4D Molecular Therapeutics Positive

Century Therapeutics has higher revenue and earnings than 4D Molecular Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Century Therapeutics$6.59M8.18-$126.57M-$0.29-2.16
4D Molecular Therapeutics$40K5,293.20-$160.87M-$3.18-1.44

Century Therapeutics currently has a consensus price target of $4.20, indicating a potential upside of 571.36%. 4D Molecular Therapeutics has a consensus price target of $29.56, indicating a potential upside of 546.73%. Given Century Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Century Therapeutics is more favorable than 4D Molecular Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Century Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
4D Molecular Therapeutics
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

Century Therapeutics beats 4D Molecular Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IPSC vs. The Competition

MetricCentury TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$56.84M$2.50B$5.70B$9.50B
Dividend YieldN/A1.75%4.60%4.01%
P/E Ratio-2.169.0528.1020.05
Price / Sales8.18592.30429.3789.38
Price / CashN/A165.2136.2258.56
Price / Book0.335.168.665.87
Net Income-$126.57M$30.99M$3.25B$258.55M
7 Day Performance7.71%7.74%4.22%3.73%
1 Month Performance10.22%16.27%10.51%11.75%
1 Year Performance-74.98%-1.88%34.40%18.03%

Century Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IPSC
Century Therapeutics
3.541 of 5 stars
$0.63
-5.2%
$4.20
+571.4%
-73.7%$56.84M$6.59M-2.16170Positive News
FDMT
4D Molecular Therapeutics
2.3878 of 5 stars
$4.24
+0.5%
$29.56
+597.1%
-75.3%$195.49M$40K-1.33120News Coverage
YMAB
Y-mAbs Therapeutics
3.654 of 5 stars
$4.33
+0.5%
$15.60
+260.3%
-61.3%$195.17M$87.68M-6.77150News Coverage
Positive News
OGI
Organigram Global
1.3229 of 5 stars
$1.46
+0.7%
N/A-5.6%$194.21M$117.47M14.60860Positive News
ENGN
enGene
2.8522 of 5 stars
$3.85
+1.6%
$23.29
+504.8%
-58.9%$193.69MN/A-2.3331
RAPT
Rapt Therapeutics
4.35 of 5 stars
$11.70
+0.2%
$19.80
+69.2%
-46.7%$193.14M$1.53M-0.6180News Coverage
Analyst Upgrade
Analyst Revision
CTMX
CytomX Therapeutics
4.2338 of 5 stars
$2.38
-0.4%
$5.33
+124.1%
+69.0%$192.28M$138.10M4.96170News Coverage
Positive News
Gap Up
CYBN
Cybin
2.6925 of 5 stars
$8.03
-3.5%
$85.00
+958.5%
N/A$191.56MN/A-1.8350High Trading Volume
SXTC
China SXT Pharmaceuticals
1.2421 of 5 stars
$1.62
-1.3%
N/A-82.5%$191.04M$1.93M0.0090Gap Up
CRBU
Caribou Biosciences
2.9471 of 5 stars
$2.07
+1.0%
$8.50
+310.6%
-6.6%$190.66M$9.99M-1.28100News Coverage
Gap Up
EPRX
Eupraxia Pharmaceuticals
2.4086 of 5 stars
$5.09
-3.9%
$11.00
+116.3%
+96.1%$190.13MN/A-6.6929Analyst Forecast

Related Companies and Tools


This page (NASDAQ:IPSC) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners